VINCENT MED (01612) has released its annual results for the period ending December 31, 2025. The group reported revenue of HK$933 million, representing an increase of 16.46% compared to the previous year. Profit attributable to owners of the company was HK$104 million, a significant rise of 50.91% year-on-year. Basic earnings per share stood at 16.18 HK cents, and the board has recommended a final dividend of 2.6 HK cents per share.

The group's imaging disposables division maintained its momentum, achieving solid revenue growth. Alongside increased order volumes for existing product lines, the group made substantial progress in new business collaborations during the year, bolstered by a deeper long-term partnership with a key client, who is a leader in the global diagnostic imaging market.

On the other hand, the group's respiratory products division delivered stable revenue performance for the year, indicating signs of demand stabilization in an environment of cautious procurement. As respiratory care represents continuous and essential care, it continues to support demand for related products in both clinical and home care settings. While near-term growth for this division is expected to be moderate, it remains a significant component of the group's revenue structure and product portfolio.

Leveraging its strong manufacturing capabilities and accumulated technical expertise, the group is actively expanding its product range into new categories. Supported by a broader product offering, an expanding distribution network, and growing market acceptance, the healthcare and wellness products division, along with other product divisions, continued to demonstrate robust revenue performance. This diversification strategy not only opens up new revenue streams but also helps improve capacity utilization and operational efficiency.